MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 169.56 Billion KRW | 11.46% |
| 2022 | 152.13 Billion KRW | 10.43% |
| 2021 | 137.75 Billion KRW | 7.75% |
| 2020 | 127.85 Billion KRW | -14.39% |
| 2019 | 149.34 Billion KRW | 1.25% |
| 2018 | 147.49 Billion KRW | 5.25% |
| 2017 | 140.13 Billion KRW | -1.44% |
| 2016 | 142.17 Billion KRW | 13.65% |
| 2015 | 125.1 Billion KRW | 18.67% |
| 2014 | 105.42 Billion KRW | 1.64% |
| 2013 | 103.72 Billion KRW | 3.17% |
| 2012 | 100.53 Billion KRW | -19.97% |
| 2011 | 125.61 Billion KRW | 19.43% |
| 2010 | 105.18 Billion KRW | 8.22% |
| 2009 | 97.19 Billion KRW | 25.59% |
| 2008 | 77.39 Billion KRW | 27.02% |
| 2007 | 60.92 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 44.23 Billion KRW | 3.23% |
| 2024 Q2 | 46.08 Billion KRW | 4.18% |
| 2023 Q4 | 42.84 Billion KRW | -0.83% |
| 2023 FY | 169.56 Billion KRW | 11.46% |
| 2023 Q3 | 43.2 Billion KRW | -0.69% |
| 2023 Q2 | 43.5 Billion KRW | 8.77% |
| 2023 Q1 | 40 Billion KRW | 0.06% |
| 2022 Q2 | 40.78 Billion KRW | 18.21% |
| 2022 FY | 152.13 Billion KRW | 10.43% |
| 2022 Q1 | 34.49 Billion KRW | -2.43% |
| 2022 Q4 | 39.97 Billion KRW | 8.41% |
| 2022 Q3 | 36.87 Billion KRW | -9.57% |
| 2021 Q1 | 31.48 Billion KRW | -2.25% |
| 2021 Q2 | 35.72 Billion KRW | 13.47% |
| 2021 Q4 | 35.35 Billion KRW | 0.45% |
| 2021 Q3 | 35.19 Billion KRW | -1.47% |
| 2021 FY | 137.75 Billion KRW | 7.75% |
| 2020 FY | 127.85 Billion KRW | -14.39% |
| 2020 Q3 | 32.15 Billion KRW | 8.23% |
| 2020 Q4 | 32.2 Billion KRW | 0.17% |
| 2020 Q2 | 29.7 Billion KRW | -12.09% |
| 2020 Q1 | 33.79 Billion KRW | -12.23% |
| 2019 Q4 | 38.5 Billion KRW | -3.01% |
| 2019 FY | 149.34 Billion KRW | 1.25% |
| 2019 Q3 | 39.69 Billion KRW | 13.57% |
| 2019 Q2 | 34.95 Billion KRW | -3.45% |
| 2019 Q1 | 36.2 Billion KRW | -13.24% |
| 2018 Q3 | 34.58 Billion KRW | -5.55% |
| 2018 FY | 147.49 Billion KRW | 5.25% |
| 2018 Q1 | 34.56 Billion KRW | -5.47% |
| 2018 Q2 | 36.62 Billion KRW | 5.97% |
| 2018 Q4 | 41.72 Billion KRW | 20.63% |
| 2017 FY | 140.13 Billion KRW | -1.44% |
| 2017 Q2 | 36.75 Billion KRW | 14.5% |
| 2017 Q3 | 34.72 Billion KRW | -5.52% |
| 2017 Q1 | 32.09 Billion KRW | -10.67% |
| 2017 Q4 | 36.56 Billion KRW | 5.29% |
| 2016 Q1 | 33.36 Billion KRW | 2.56% |
| 2016 Q4 | 35.93 Billion KRW | -3.38% |
| 2016 Q3 | 37.18 Billion KRW | 4.18% |
| 2016 Q2 | 35.69 Billion KRW | 7.0% |
| 2016 FY | 142.17 Billion KRW | 13.65% |
| 2015 Q3 | 33.63 Billion KRW | 7.15% |
| 2015 Q1 | 27.55 Billion KRW | -3.18% |
| 2015 Q4 | 32.52 Billion KRW | -3.28% |
| 2015 Q2 | 31.38 Billion KRW | 13.91% |
| 2015 FY | 125.1 Billion KRW | 18.67% |
| 2014 Q3 | 27.23 Billion KRW | 6.02% |
| 2014 Q2 | 25.68 Billion KRW | 6.83% |
| 2014 Q4 | 28.45 Billion KRW | 4.51% |
| 2014 Q1 | 24.04 Billion KRW | -3.16% |
| 2014 FY | 105.42 Billion KRW | 1.64% |
| 2013 Q3 | 25.64 Billion KRW | -4.47% |
| 2013 FY | 103.72 Billion KRW | 3.17% |
| 2013 Q2 | 26.83 Billion KRW | 1.61% |
| 2013 Q4 | 24.82 Billion KRW | -3.17% |
| 2013 Q1 | 26.41 Billion KRW | 0.88% |
| 2012 Q1 | 29.62 Billion KRW | 0.0% |
| 2012 FY | 100.53 Billion KRW | -19.97% |
| 2012 Q2 | 19.61 Billion KRW | -33.81% |
| 2012 Q3 | 24.54 Billion KRW | 25.17% |
| 2012 Q4 | 26.18 Billion KRW | 6.67% |
| 2011 Q1 | 29.27 Billion KRW | 0.0% |
| 2011 Q3 | 30.37 Billion KRW | 1.7% |
| 2011 FY | 125.61 Billion KRW | 19.43% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 29.86 Billion KRW | 2.01% |
| 2010 Q1 | 23.63 Billion KRW | 0.0% |
| 2010 Q3 | 25.76 Billion KRW | -3.81% |
| 2010 FY | 105.18 Billion KRW | 8.22% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 26.78 Billion KRW | 13.31% |
| 2009 Q3 | 23.03 Billion KRW | -0.46% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 97.19 Billion KRW | 25.59% |
| 2009 Q1 | 22.4 Billion KRW | 1.5% |
| 2009 Q2 | 23.13 Billion KRW | 3.26% |
| 2008 Q3 | 17.56 Billion KRW | -10.35% |
| 2008 Q4 | 22.07 Billion KRW | 25.66% |
| 2008 Q2 | 19.59 Billion KRW | 0.0% |
| 2008 FY | 77.39 Billion KRW | 27.02% |
| 2007 FY | 60.92 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -23.583% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 85.021% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 73.441% |
| HANDOK Inc. | 522.74 Billion KRW | 67.562% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -25.26% |
| Yuhan Corporation | 1858.98 Billion KRW | 90.878% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 74.462% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -226.373% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 88.626% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -25.689% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 54.237% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -91.399% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 24.454% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -23.583% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -117.246% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -12.243% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -94.094% |
| JW Holdings Corporation | 928.07 Billion KRW | 81.729% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 71.774% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 89.843% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 77.347% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 15.313% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 6.193% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 13.638% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 76.656% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -23.583% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 88.803% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 87.671% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 77.347% |
| Yuhan Corporation | 1858.98 Billion KRW | 90.878% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 78.663% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 27.814% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 71.481% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 77.347% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 41.955% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 39.211% |
| CKD Bio Corp. | 160.35 Billion KRW | -5.746% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 67.821% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 53.043% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 26.401% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 15.313% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 80.726% |
| Boryung Corporation | 859.62 Billion KRW | 80.274% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -34.654% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 54.237% |
| JW Lifescience Corporation | 206.86 Billion KRW | 18.028% |